KOR

e-Article

A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan
Document Type
Article
Source
In Annals of Oncology July 2002 13(7):1067-1071
Subject
Language
ISSN
0923-7534